ID   AFAD_HUMAN              Reviewed;        1824 AA.
AC   P55196; O75087; O75088; O75089; Q59FP0; Q5TIG6; Q5TIG7; Q9NSN7; Q9NU92;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   09-FEB-2010, sequence version 3.
DT   28-JUN-2023, entry version 225.
DE   RecName: Full=Afadin;
DE   AltName: Full=ALL1-fused gene from chromosome 6 protein;
DE            Short=Protein AF-6;
DE   AltName: Full=Afadin adherens junction formation factor {ECO:0000312|HGNC:HGNC:7137};
GN   Name=AFDN {ECO:0000312|HGNC:HGNC:7137}; Synonyms=AF6, MLLT4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHROMOSOMAL TRANSLOCATION WITH
RP   KMT2A.
RX   PubMed=8242616;
RA   Prasad R., Gu Y., Alder H., Nakamura T., Canaani O., Saito H., Huebner K.,
RA   Gale R.P., Nowell P.C., Kuriyama K., Miyazaki Y., Croce C.M., Canaani E.;
RT   "Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute
RT   myeloid leukemias with the t(6;11) chromosome translocation.";
RL   Cancer Res. 53:5624-5628(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1; 2
RP   AND 3).
RC   TISSUE=Fetal brain;
RX   PubMed=9679199; DOI=10.1093/dnares/5.2.115;
RA   Saito S., Matsushima M., Shirahama S., Minaguchi T., Kanamori Y.,
RA   Minami M., Nakamura Y.;
RT   "Complete genomic structure, DNA polymorphisms, and alternative splicing of
RT   the human AF-6 gene.";
RL   DNA Res. 5:115-120(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 13-1824 (ISOFORM 6).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 335-1824 (ISOFORM 5).
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH NECTIN3.
RX   PubMed=11024295; DOI=10.1016/s0378-1119(00)00316-4;
RA   Reymond N., Borg J.-P., Lecocq E., Adelaide J., Campadelli-Fiume G.,
RA   Dubreuil P., Lopez M.;
RT   "Human nectin3/PRR3: a novel member of the PVR/PRR/nectin family that
RT   interacts with afadin.";
RL   Gene 255:347-355(2000).
RN   [8]
RP   REVIEW ON INTERACTION.
RX   PubMed=12456712; DOI=10.1242/jcs.00167;
RA   Takai Y., Nakanishi H.;
RT   "Nectin and afadin: novel organizers of intercellular junctions.";
RL   J. Cell Sci. 116:17-27(2003).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1182, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1182, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17693683; DOI=10.1074/mcp.m700120-mcp200;
RA   Tang L.-Y., Deng N., Wang L.-S., Dai J., Wang Z.-L., Jiang X.-S., Li S.-J.,
RA   Li L., Sheng Q.-H., Wu D.-Q., Li L., Zeng R.;
RT   "Quantitative phosphoproteome profiling of Wnt3a-mediated signaling
RT   network: indicating the involvement of ribonucleoside-diphosphate reductase
RT   M2 subunit phosphorylation at residue serine 20 in canonical Wnt signal
RT   transduction.";
RL   Mol. Cell. Proteomics 6:1952-1967(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-1107; SER-1182;
RP   THR-1232; SER-1721; SER-1779 AND SER-1799, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1182 AND SER-1721, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1721; SER-1779 AND SER-1799,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216; SER-256; SER-424;
RP   SER-512; SER-557; SER-562; SER-589; SER-655; SER-1083; SER-1107; SER-1143;
RP   SER-1173; SER-1182; SER-1199; THR-1232; SER-1238; SER-1275; SER-1328;
RP   THR-1330; SER-1501; SER-1512 AND SER-1721, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-246; SER-1182; THR-1211;
RP   SER-1696 AND SER-1799, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   FUNCTION, INTERACTION WITH ADAM10, AND SUBCELLULAR LOCATION.
RX   PubMed=30463011; DOI=10.1016/j.celrep.2018.10.088;
RA   Shah J., Rouaud F., Guerrera D., Vasileva E., Popov L.M., Kelley W.L.,
RA   Rubinstein E., Carette J.E., Amieva M.R., Citi S.;
RT   "A Dock-and-Lock Mechanism Clusters ADAM10 at Cell-Cell Junctions to
RT   Promote alpha-Toxin Cytotoxicity.";
RL   Cell Rep. 25:2132-2147(2018).
RN   [20]
RP   STRUCTURE BY NMR OF 1003-1094 IN COMPLEX WITH NRXN1 AND BCR.
RX   PubMed=15684424; DOI=10.1074/jbc.m411065200;
RA   Zhou H., Xu Y., Yang Y., Huang A., Wu J., Shi Y.;
RT   "Solution structure of AF-6 PDZ domain and its interaction with the C-
RT   terminal peptides from Neurexin and Bcr.";
RL   J. Biol. Chem. 280:13841-13847(2005).
RN   [21]
RP   STRUCTURE BY NMR OF 1001-1095.
RX   PubMed=16671149; DOI=10.1002/anie.200503965;
RA   Joshi M., Vargas C., Boisguerin P., Diehl A., Krause G., Schmieder P.,
RA   Moelling K., Hagen V., Schade M., Oschkinat H.;
RT   "Discovery of low-molecular-weight ligands for the AF6 PDZ domain.";
RL   Angew. Chem. Int. Ed. 45:3790-3795(2006).
CC   -!- FUNCTION: Belongs to an adhesion system, probably together with the E-
CC       cadherin-catenin system, which plays a role in the organization of
CC       homotypic, interneuronal and heterotypic cell-cell adherens junctions
CC       (AJs) (By similarity). Nectin- and actin-filament-binding protein that
CC       connects nectin to the actin cytoskeleton (PubMed:11024295). May play a
CC       key role in the organization of epithelial structures of the embryonic
CC       ectoderm (By similarity). Essential for the organization of adherens
CC       junctions (PubMed:30463011). {ECO:0000250|UniProtKB:O35889,
CC       ECO:0000250|UniProtKB:Q9QZQ1, ECO:0000269|PubMed:11024295,
CC       ECO:0000269|PubMed:30463011}.
CC   -!- SUBUNIT: Homodimer. Interacts with F-actin, nectin and NECTIN3.
CC       Essential for the association of nectin and E-cadherin. Isoform 1/s-
CC       afadin does not interact with F-actin. Interacts with ZO-1 and
CC       occludin, but probably in an indirect manner. Interacts with RIT1 and
CC       RIT2 (By similarity). Interacts with NRXN1 and BCR. Interacts with
CC       ADAM10; the interaction locks ADAM10 at adherens junctions following
CC       ADAM10 recruitment to adherens junctions by TSPAN33 (PubMed:30463011).
CC       {ECO:0000250, ECO:0000269|PubMed:11024295, ECO:0000269|PubMed:15684424,
CC       ECO:0000269|PubMed:30463011}.
CC   -!- INTERACTION:
CC       P55196; Q16643: DBN1; NbExp=4; IntAct=EBI-365875, EBI-351394;
CC       P55196; Q92692: NECTIN2; NbExp=2; IntAct=EBI-365875, EBI-718419;
CC       P55196; P12931: SRC; NbExp=7; IntAct=EBI-365875, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Cell junction, adherens junction
CC       {ECO:0000269|PubMed:30463011}. Note=Not found at cell-matrix AJs.
CC       {ECO:0000250|UniProtKB:O35889}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=4;
CC         IsoId=P55196-4; Sequence=Displayed;
CC       Name=1; Synonyms=s-afadin;
CC         IsoId=P55196-2; Sequence=VSP_038707, VSP_038708, VSP_000217,
CC                                  VSP_000218;
CC       Name=2; Synonyms=l-afadin;
CC         IsoId=P55196-1; Sequence=VSP_038707, VSP_038708, VSP_038709,
CC                                  VSP_038711;
CC       Name=3;
CC         IsoId=P55196-3; Sequence=VSP_038707, VSP_038708, VSP_038709,
CC                                  VSP_038710;
CC       Name=6;
CC         IsoId=P55196-6; Sequence=VSP_041197, VSP_041198, VSP_041199;
CC       Name=5;
CC         IsoId=P55196-5; Sequence=VSP_038707, VSP_019257;
CC   -!- DOMAIN: The PDZ/DHR domain interacts with the C-terminus of nectin and
CC       the Pro-rich C-terminal domain interacts with F-actin.
CC   -!- DISEASE: Note=A chromosomal aberration involving AFDN is associated
CC       with acute leukemias. Translocation t(6;11)(q27;q23) with KMT2A/MLL1.
CC       The result is a rogue activator protein.
CC   -!- MISCELLANEOUS: [Isoform 1]: May be due to intron retention.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to intron retention.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAB82312.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/6/AF6";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U02478; AAC50059.1; -; mRNA.
DR   EMBL; AB011399; BAA32483.1; -; Genomic_DNA.
DR   EMBL; AB011399; BAA32484.1; -; Genomic_DNA.
DR   EMBL; AB011399; BAA32485.1; -; Genomic_DNA.
DR   EMBL; AL009178; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL049698; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL731868; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47482.1; -; Genomic_DNA.
DR   EMBL; AB209420; BAD92657.1; -; mRNA.
DR   EMBL; AL161973; CAB82312.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS47517.1; -. [P55196-6]
DR   CCDS; CCDS75553.1; -. [P55196-3]
DR   CCDS; CCDS94034.1; -. [P55196-4]
DR   PIR; T47137; T47137.
DR   RefSeq; NP_001035089.1; NM_001040000.2. [P55196-6]
DR   RefSeq; NP_001193937.1; NM_001207008.1. [P55196-3]
DR   RefSeq; NP_001278893.1; NM_001291964.1.
DR   RefSeq; XP_005267053.1; XM_005266996.3.
DR   PDB; 1T2M; NMR; -; A=1003-1094.
DR   PDB; 1XZ9; NMR; -; A=1001-1096.
DR   PDB; 2AIN; NMR; -; A=1003-1094.
DR   PDB; 2EXG; NMR; -; A=1001-1096.
DR   PDB; 5A6C; X-ray; 2.90 A; A/B=1709-1746.
DR   PDB; 7QCR; X-ray; 2.28 A; A/B=1002-1097.
DR   PDBsum; 1T2M; -.
DR   PDBsum; 1XZ9; -.
DR   PDBsum; 2AIN; -.
DR   PDBsum; 2EXG; -.
DR   PDBsum; 5A6C; -.
DR   PDBsum; 7QCR; -.
DR   AlphaFoldDB; P55196; -.
DR   BMRB; P55196; -.
DR   SMR; P55196; -.
DR   BioGRID; 110447; 301.
DR   CORUM; P55196; -.
DR   ELM; P55196; -.
DR   IntAct; P55196; 55.
DR   MINT; P55196; -.
DR   STRING; 9606.ENSP00000375960; -.
DR   DrugBank; DB08574; (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one.
DR   GlyGen; P55196; 4 sites, 1 O-linked glycan (4 sites).
DR   iPTMnet; P55196; -.
DR   PhosphoSitePlus; P55196; -.
DR   SwissPalm; P55196; -.
DR   BioMuta; AFDN; -.
DR   DMDM; 288558835; -.
DR   EPD; P55196; -.
DR   jPOST; P55196; -.
DR   MassIVE; P55196; -.
DR   MaxQB; P55196; -.
DR   PaxDb; P55196; -.
DR   PeptideAtlas; P55196; -.
DR   ProteomicsDB; 56796; -. [P55196-4]
DR   ProteomicsDB; 56797; -. [P55196-1]
DR   ProteomicsDB; 56798; -. [P55196-2]
DR   ProteomicsDB; 56799; -. [P55196-3]
DR   ProteomicsDB; 56800; -. [P55196-5]
DR   ProteomicsDB; 56801; -. [P55196-6]
DR   Antibodypedia; 4608; 296 antibodies from 33 providers.
DR   DNASU; 4301; -.
DR   Ensembl; ENST00000392108.7; ENSP00000375956.3; ENSG00000130396.22. [P55196-6]
DR   Ensembl; ENST00000392112.5; ENSP00000375960.2; ENSG00000130396.22. [P55196-3]
DR   Ensembl; ENST00000400822.7; ENSP00000383623.3; ENSG00000130396.22. [P55196-5]
DR   Ensembl; ENST00000447894.6; ENSP00000404595.2; ENSG00000130396.22. [P55196-4]
DR   GeneID; 4301; -.
DR   KEGG; hsa:4301; -.
DR   UCSC; uc003qwc.3; human. [P55196-4]
DR   AGR; HGNC:7137; -.
DR   CTD; 4301; -.
DR   DisGeNET; 4301; -.
DR   GeneCards; AFDN; -.
DR   HGNC; HGNC:7137; AFDN.
DR   HPA; ENSG00000130396; Low tissue specificity.
DR   MIM; 159559; gene.
DR   neXtProt; NX_P55196; -.
DR   OpenTargets; ENSG00000130396; -.
DR   VEuPathDB; HostDB:ENSG00000130396; -.
DR   eggNOG; KOG1892; Eukaryota.
DR   GeneTree; ENSGT00940000155237; -.
DR   InParanoid; P55196; -.
DR   OrthoDB; 2881454at2759; -.
DR   PhylomeDB; P55196; -.
DR   TreeFam; TF350731; -.
DR   PathwayCommons; P55196; -.
DR   Reactome; R-HSA-418990; Adherens junctions interactions. [P55196-2]
DR   SignaLink; P55196; -.
DR   SIGNOR; P55196; -.
DR   BioGRID-ORCS; 4301; 46 hits in 1162 CRISPR screens.
DR   ChiTaRS; AFDN; human.
DR   EvolutionaryTrace; P55196; -.
DR   GeneWiki; MLLT4; -.
DR   GenomeRNAi; 4301; -.
DR   Pharos; P55196; Tbio.
DR   PRO; PR:P55196; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P55196; protein.
DR   Bgee; ENSG00000130396; Expressed in right uterine tube and 179 other tissues.
DR   ExpressionAtlas; P55196; baseline and differential.
DR   Genevisible; P55196; HS.
DR   GO; GO:0005912; C:adherens junction; IBA:GO_Central.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0044291; C:cell-cell contact zone; IDA:ARUK-UCL.
DR   GO; GO:0005911; C:cell-cell junction; IDA:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0046930; C:pore complex; IMP:UniProtKB.
DR   GO; GO:0070160; C:tight junction; IDA:ARUK-UCL.
DR   GO; GO:0051015; F:actin filament binding; IDA:ARUK-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IBA:GO_Central.
DR   GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IMP:ARUK-UCL.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; ISS:ARUK-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0090557; P:establishment of endothelial intestinal barrier; IMP:UniProtKB.
DR   GO; GO:0061951; P:establishment of protein localization to plasma membrane; ISS:ARUK-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:ARUK-UCL.
DR   GO; GO:0046931; P:pore complex assembly; IMP:UniProtKB.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IMP:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0032880; P:regulation of protein localization; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd22711; FHA_AFDN; 1.
DR   CDD; cd15471; Myo5p-like_CBD_afadin; 1.
DR   CDD; cd00992; PDZ_signaling; 1.
DR   CDD; cd01782; RA1_Afadin; 1.
DR   CDD; cd01781; RA2_Afadin; 1.
DR   Gene3D; 2.30.42.10; -; 1.
DR   Gene3D; 2.60.200.20; -; 1.
DR   InterPro; IPR037977; CBD_Afadin.
DR   InterPro; IPR002710; Dilute_dom.
DR   InterPro; IPR000253; FHA_dom.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR036034; PDZ_sf.
DR   InterPro; IPR000159; RA_dom.
DR   InterPro; IPR008984; SMAD_FHA_dom_sf.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR10398; AFADIN; 1.
DR   PANTHER; PTHR10398:SF2; AFADIN; 1.
DR   Pfam; PF01843; DIL; 1.
DR   Pfam; PF00498; FHA; 1.
DR   Pfam; PF00595; PDZ; 1.
DR   Pfam; PF00788; RA; 2.
DR   SMART; SM01132; DIL; 1.
DR   SMART; SM00240; FHA; 1.
DR   SMART; SM00228; PDZ; 1.
DR   SMART; SM00314; RA; 2.
DR   SUPFAM; SSF50156; PDZ domain-like; 1.
DR   SUPFAM; SSF49879; SMAD/FHA domain; 1.
DR   SUPFAM; SSF54236; Ubiquitin-like; 2.
DR   PROSITE; PS51126; DILUTE; 1.
DR   PROSITE; PS50106; PDZ; 1.
DR   PROSITE; PS50200; RA; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell adhesion;
KW   Cell junction; Chromosomal rearrangement; Coiled coil; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Repeat.
FT   CHAIN           1..1824
FT                   /note="Afadin"
FT                   /id="PRO_0000215918"
FT   DOMAIN          39..133
FT                   /note="Ras-associating 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00166"
FT   DOMAIN          246..348
FT                   /note="Ras-associating 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00166"
FT   DOMAIN          426..492
FT                   /note="FHA"
FT   DOMAIN          668..908
FT                   /note="Dilute"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00503"
FT   DOMAIN          1007..1093
FT                   /note="PDZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   REGION          128..194
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          349..378
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          534..595
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1107..1223
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1235..1473
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1501..1528
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1569..1824
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          146..185
FT                   /evidence="ECO:0000255"
FT   COILED          1408..1448
FT                   /evidence="ECO:0000255"
FT   COILED          1523..1667
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        143..194
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        349..369
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        544..568
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1129..1145
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1154..1169
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1171..1209
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1274..1300
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1302..1340
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1360..1375
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1406..1442
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1443..1473
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1514..1528
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1590..1676
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1682..1711
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1762..1776
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1777..1808
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1809..1824
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            26
FT                   /note="Breakpoint for translocation to form KMT2A/MLL1-
FT                   AFDN"
FT   MOD_RES         216
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         256
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         391
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O35889"
FT   MOD_RES         424
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         512
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         557
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         562
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         589
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         655
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1083
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1107
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1126
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZQ1"
FT   MOD_RES         1140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O35889"
FT   MOD_RES         1143
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1172
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZQ1"
FT   MOD_RES         1173
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1182
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:17693683, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1199
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1211
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1232
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1238
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1275
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1330
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1501
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1512
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1696
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1721
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1774
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZQ1"
FT   MOD_RES         1779
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         1799
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1807
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZQ1"
FT   VAR_SEQ         139
FT                   /note="Missing (in isoform 1, isoform 2, isoform 3 and
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:17974005,
FT                   ECO:0000303|PubMed:8242616"
FT                   /id="VSP_038707"
FT   VAR_SEQ         393..407
FT                   /note="Missing (in isoform 1, isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8242616"
FT                   /id="VSP_038708"
FT   VAR_SEQ         1048
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_038709"
FT   VAR_SEQ         1604
FT                   /note="R -> RTAMPAISVLDL (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_019257"
FT   VAR_SEQ         1605..1628
FT                   /note="LQDEERRRQQQLEEMRKREAEDRA -> VKGGVLWLCPSVVPILASACFPWG
FT                   (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:8242616"
FT                   /id="VSP_000217"
FT   VAR_SEQ         1605..1606
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_041197"
FT   VAR_SEQ         1629..1824
FT                   /note="Missing (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:8242616"
FT                   /id="VSP_000218"
FT   VAR_SEQ         1650..1653
FT                   /note="RRQE -> VMVL (in isoform 6)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_041198"
FT   VAR_SEQ         1654..1824
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_041199"
FT   VAR_SEQ         1683..1746
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_038710"
FT   VAR_SEQ         1747..1824
FT                   /note="PNSYPGSTGAAVGAHDACRDAKEKRSKSQDADSPGSSGAPENLTFKERQRLF
FT                   SQGQDVSNKVKASRKLTELENELNTK -> QDKYSSTRKSHGDLLPAPLKPRPPPCQPR
FT                   PASDGVFLSNSFQPPSAKANSTAHKKGQPLPPPKKSSSYHPSHCKGRGKRVTNQLSLS
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_038711"
FT   CONFLICT        374
FT                   /note="G -> V (in Ref. 1; AAC50059)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1425
FT                   /note="R -> P (in Ref. 1; AAC50059)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1007..1013
FT                   /evidence="ECO:0007829|PDB:7QCR"
FT   STRAND          1015..1017
FT                   /evidence="ECO:0007829|PDB:1T2M"
FT   STRAND          1020..1025
FT                   /evidence="ECO:0007829|PDB:7QCR"
FT   STRAND          1028..1031
FT                   /evidence="ECO:0007829|PDB:1XZ9"
FT   STRAND          1034..1040
FT                   /evidence="ECO:0007829|PDB:7QCR"
FT   STRAND          1042..1044
FT                   /evidence="ECO:0007829|PDB:1XZ9"
FT   HELIX           1045..1049
FT                   /evidence="ECO:0007829|PDB:7QCR"
FT   STRAND          1057..1061
FT                   /evidence="ECO:0007829|PDB:7QCR"
FT   HELIX           1071..1079
FT                   /evidence="ECO:0007829|PDB:7QCR"
FT   STRAND          1083..1090
FT                   /evidence="ECO:0007829|PDB:7QCR"
FT   TURN            1722..1724
FT                   /evidence="ECO:0007829|PDB:5A6C"
FT   TURN            1735..1738
FT                   /evidence="ECO:0007829|PDB:5A6C"
FT   CONFLICT        P55196-2:1031..1032
FT                   /note="DV -> D (in Ref. 1; AAC50059 and 2; BAA32485)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1824 AA;  206804 MW;  51486232F183A3BA CRC64;
     MSAGGRDEER RKLADIIHHW NANRLDLFEI SQPTEDLEFH GVMRFYFQDK AAGNFATKCI
     RVSSTATTQD VIETLAEKFR PDMRMLSSPK YSLYEVHVSG ERRLDIDEKP LVVQLNWNKD
     DREGRFVLKN ENDAIPPKKA QSNGPEKQEK EGVIQNFKRT LSKKEKKEKK KREKEALRQA
     SDKDDRPFQG EDVENSRLAA EVYKDMPETS FTRTISNPEV VMKRRRQQKL EKRMQEFRSS
     DGRPDSGGTL RIYADSLKPN IPYKTILLST TDPADFAVAE ALEKYGLEKE NPKDYCIARV
     MLPPGAQHSD EKGAKEIILD DDECPLQIFR EWPSDKGILV FQLKRRPPDH IPKKTKKHLE
     GKTPKGKERA DGSGYGSTLP PEKLPYLVEL SPGRRNHFAY YNYHTYEDGS DSRDKPKLYR
     LQLSVTEVGT EKLDDNSIQL FGPGIQPHHC DLTNMDGVVT VTPRSMDAET YVEGQRISET
     TMLQSGMKVQ FGASHVFKFV DPSQDHALAK RSVDGGLMVK GPRHKPGIVQ ETTFDLGGDI
     HSGTALPTSK STTRLDSDRV SSASSTAERG MVKPMIRVEQ QPDYRRQESR TQDASGPELI
     LPASIEFRES SEDSFLSAII NYTNSSTVHF KLSPTYVLYM ACRYVLSNQY RPDISPTERT
     HKVIAVVNKM VSMMEGVIQK QKNIAGALAF WMANASELLN FIKQDRDLSR ITLDAQDVLA
     HLVQMAFKYL VHCLQSELNN YMPAFLDDPE ENSLQRPKID DVLHTLTGAM SLLRRCRVNA
     ALTIQLFSQL FHFINMWLFN RLVTDPDSGL CSHYWGAIIR QQLGHIEAWA EKQGLELAAD
     CHLSRIVQAT TLLTMDKYAP DDIPNINSTC FKLNSLQLQA LLQNYHCAPD EPFIPTDLIE
     NVVTVAENTA DELARSDGRE VQLEEDPDLQ LPFLLPEDGY SCDVVRNIPN GLQEFLDPLC
     QRGFCRLIPH TRSPGTWTIY FEGADYESHL LRENTELAQP LRKEPEIITV TLKKQNGMGL
     SIVAAKGAGQ DKLGIYVKSV VKGGAADVDG RLAAGDQLLS VDGRSLVGLS QERAAELMTR
     TSSVVTLEVA KQGAIYHGLA TLLNQPSPMM QRISDRRGSG KPRPKSEGFE LYNNSTQNGS
     PESPQLPWAE YSEPKKLPGD DRLMKNRADH RSSPNVANQP PSPGGKSAYA SGTTAKITSV
     STGNLCTEEQ TPPPRPEAYP IPTQTYTREY FTFPASKSQD RMAPPQNQWP NYEEKPHMHT
     DSNHSSIAIQ RVTRSQEELR EDKAYQLERH RIEAAMDRKS DSDMWINQSS SLDSSTSSQE
     HLNHSSKSVT PASTLTKSGP GRWKTPAAIP ATPVAVSQPI RTDLPPPPPP PPVHYAGDFD
     GMSMDLPLPP PPSANQIGLP SAQVAAAERR KREEHQRWYE KEKARLEEER ERKRREQERK
     LGQMRTQSLN PAPFSPLTAQ QMKPEKPSTL QRPQETVIRE LQPQQQPRTI ERRDLQYITV
     SKEELSSGDS LSPDPWKRDA KEKLEKQQQM HIVDMLSKEI QELQSKPDRS AEESDRLRKL
     MLEWQFQKRL QESKQKDEDD EEEEDDDVDT MLIMQRLEAE RRARLQDEER RRQQQLEEMR
     KREAEDRARQ EEERRRQEEE RTKRDAEEKR RQEEGYYSRL EAERRRQHDE AARRLLEPEA
     PGLCRPPLPR DYEPPSPSPA PGAPPPPPQR NASYLKTQVL SPDSLFTAKF VAYNEEEEEE
     DCSLAGPNSY PGSTGAAVGA HDACRDAKEK RSKSQDADSP GSSGAPENLT FKERQRLFSQ
     GQDVSNKVKA SRKLTELENE LNTK
//
